ARV-471 is currently in a phase 2 trial for the treatment of patients ER-positive, HER2-negative locally advanced or metastatic breast cancer
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.